Cargando…
Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection
BACKGROUND: Candida auris is an emerging, nosocomial multidrug-resistant threat with high treatment failure rate and mortality. The optimal antifungal agent to use and susceptibility breakpoints are based on limited clinical data. METHODS: Nine clinical C. auris strains were used. MICs were determin...
Autores principales: | Lepak, Alexander J, Zhao, Miao, Berkow, Elizabeth, Lockhart, Shawn, Andes, David R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632186/ http://dx.doi.org/10.1093/ofid/ofx163.004 |
Ejemplares similares
-
In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model
por: Lepak, Alexander J, et al.
Publicado: (2017) -
1383. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, Against E. coli (EC) and K. pneumoniae (KPN) in the Murine Neutropenic Thigh Model
por: Zhao, Miao, et al.
Publicado: (2018) -
First Nine Cases of Candida auris Infection Reported in Central America: Importance of Acurate Diagnosis and Susceptibility Testing
por: Rodriguez, Ana Belen Arauz, et al.
Publicado: (2017) -
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
por: Ghannoum, Mahmoud, et al.
Publicado: (2020) -
672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)